Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Completed · Phase 1
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Vaccines made from a person's dendritic cells mixed with tumor peptides and proteins may help the body build an effective immune response to kill tumor cells. Infusing the vaccine directly into the lymphatic system may cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of two dendritic cell vaccines in treating patients with stage III or stage IV melanoma.
Key facts
- Study ID
- NCT00390338
- Run by
- Pawel Kalinski
- People needed
- 22
- Starts
- 2006-10-01
- Expected to finish
- 2015-01-01
- Last updated by the study team
- 2017-09-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UPMC Cancer Center at Magee-Womens Hospital — Pittsburgh, Pennsylvania, United States
- UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.